Valeant Cuts Forecast; Stock Plummets by Half

Mar 15, 2016

CNBC

Shares of Valeant Pharmaceuticals dropped drastically -- by 51 percent -- on Tuesday after the company cut its 2016 revenue forecast by about 12 percent and said a delay in filing its annual report could violate some of its debt agreements, according to a CNBC report.

Defaulting on debt could allow lenders to demand faster repayment and restrict Valeant's ability to borrow in the future, the report continued.

A prominent investor, Bill Ackman, said he is still confident in Valeant and he plans to be more proactive in his dealings with the company. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments